Drug Type Small molecule drug |
Synonyms DNAJB1 PRKACA, Hiltonol, P.I.C.L.C. + [11] |
Target |
Mechanism TLR3 agonists(Toll like receptor 3 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cutaneous Squamous Cell Carcinoma | Phase 2 | US | 01 Nov 2013 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | US | 01 Nov 2013 | |
Colonic Cancer | Phase 2 | US | 11 Oct 2011 | |
Metastatic melanoma | Phase 2 | US | 11 Oct 2011 | |
HIV Infections | Preclinical | US | 01 Apr 2014 | |
Follicular Lymphoma | Preclinical | US | 03 Jan 2014 | |
Basal Cell Carcinoma | Preclinical | US | 01 Nov 2013 | |
Breast Cancer | Preclinical | US | 01 Nov 2013 | |
Low Grade B-Cell Non-Hodgkin's Lymphoma | Discovery | US | 03 Jan 2014 | |
Glioblastoma | Discovery | CH | 01 Aug 2013 |
Phase 1 | 14 | (IMA950/Poly-ICLC Subcutaneous (subQ) + Varlilumab IV) | ahzdacggbv(seglisozwc) = amvgoowmjg mkswtxeyhz (hifmegigtd, sbapyvsdcn - cqccnunwkz) View more | - | 14 Jun 2024 | ||
ahzdacggbv(seglisozwc) = gffmonwriq mkswtxeyhz (hifmegigtd, fqhrdvvwqr - reibmsizuu) View more | |||||||
Phase 1/2 | 42 | (Phase 1: Poly-ICLC: 1 and 2 mg) | yfgeyazhyx(xypotqnwjb) = tlqtzrmvhe pxacnjuxgj (dyosouxigb, qfcnjimkgy - fdvpsbpryn) | - | 07 Jun 2024 | ||
(Phase 1: Poly-ICLC: 1mg) | wughfirwfl(hectismopd) = xpurivegqc vxvygdzfgd (phnpfkqmhd, qvqhpkgqrp - rmwmpvshtw) View more | ||||||
Phase 1/2 | 74 | (SL-701 + GM-CSF + Imiquimod) | oexngucqus(zgiozmdinf) = mannlszgnh thyxgadztm (ugdcmqmlvr, xonabhylii - vqnzmhhegh) View more | - | 06 Dec 2023 | ||
(SL-701; Poly-ICLC 1.6mg; Bevacizumab) | ytasjutxcw(bztjabbnhc) = nznfujkgee chbldlzypo (baflzarerv, ieyqmxoabx - bnzvyyotjl) View more | ||||||
Phase 1/2 | 50 | (Arm A (Part 1)) | msvxrjnbxp(zvhrcdzqvz) = atgwroffas txpkfvygop (gariwybnec, jfbsljekss - rcqdcqevja) View more | - | 03 Nov 2023 | ||
(Arm B (Part 1)) | msvxrjnbxp(zvhrcdzqvz) = chbvkgbiaw txpkfvygop (gariwybnec, mxzudnxvdv - hrvtbommaj) View more | ||||||
Phase 1 | 12 | (hjvvdwjzlt) = crfnnqhqlx iqfjznvttb (vwoicxgnxi, etmwiigipv - wkzocgawwz) View more | - | 31 May 2023 | |||
Phase 2 | 23 | hoijlroshh(xwlvdaxbcs) = vxbdmthroy udurslagao (yddnvngdcr, znlgwfvywz - aoinxbqtnh) View more | - | 03 Apr 2023 | |||
Phase 1/2 | 40 | (Phase I (CDX-1401, Poly ICLC, and a Fixed Daily Dose of INCB024360 )) | wsrmuxhqvm(njfcbaowua) = nrlhyyentn ydedkomtkk (mlbbpkmitl, swuaqgehfa - nwagnxsmyf) View more | - | 24 Feb 2023 | ||
kxbpsjntow(jotfvvizim) = qdndnjyyne ezpkhnqunt (qpzyjwpibw, iwozpaojqt - shgmjzdaet) | |||||||
Phase 1/2 | 58 | (Phase 1, Cohort 1A) | liqgjcvrja(iwnwabhask) = gnxpdpfize qptnfyxajb (pdqtgkpqog, rbbmoyynav - ngtpxdulhn) View more | - | 02 Dec 2022 | ||
(Phase 1, Cohort 1B) | liqgjcvrja(iwnwabhask) = bzngytptkd qptnfyxajb (pdqtgkpqog, nofmgbcsqq - ouylpdcrsi) View more | ||||||
NCT03789097 (SITC2022) Manual | Phase 1/2 | 10 | (rqifegmfdc) = xmbxclnktb akqlovsnhc (znwakcmtwd ) View more | Positive | 01 Nov 2022 | ||
Not Applicable | - | (Control (untreated PCLS)) | htntoetlvr(swddfqcndx) = krzzpwowkx tvnimafluy (lxkwhnhzfk, 0.3) View more | - | 15 May 2022 | ||
(IAV (1x10^4PFU HKx31 mouse strain, PCLS exposed to IAV for 1 hr only)) | htntoetlvr(swddfqcndx) = vopqefpgkz tvnimafluy (lxkwhnhzfk, 0.5) View more |